Introduction
Staphylococcus azuezu is one of the most important causes of nosocomialand community-acquired infections. Although staphylococci are common inhabitants of the skin and the mucous membranes, the anterior nares provide the principal reservoir for these organisms. The general population, health care workers and patients can become intermittent or persistent nasal carriers of S. auyeus, although the prevalence of nasal carriage varies widely depending upon the population. ' Studies have shown that 1 O-l 5% of healthy adults carry S. aUreUS in their nares; this figure rises to approximately 20-35% in hospital personnel.* Many patient groups have higher rates of S. atireUS nasal carriage in comparison to the general population and health care workers, such as patients infected with HIV and those treated by haemodialysis and continuous ambulatory peritoneal dialysis (CAPD). Chronic carriers, therefore, appear to be at a higher risk of developing S. aureus-related infections. In a subsequent study by Kim et aZ.14 10 of 12 CAPD patients were found to have isolates of the same phage-type in cultures of the exit-site and peritoneal fluid. Furthermore, of the 12 patients, seven had isolates with the same phage-type in cultures from the nares, hands and peritoneal fluid. In a study in which the number of exit-site infections in 87 CAPD patients was recorded over eight months, patients who were nasal carriers were found to have a 6,7-fold increase in the incidence of exit-site infections compared with patients with negative cultures of the nares.5 In a similar study in which 43 patients, 16 chronic carriers and 12 intermittent carriers, underwent CAPD prospectively for 15 months, 16 episodes of peritonitis occurred in the carrier group compared with none in the non-carrier group. Moreover, of those patients evaluated, 100% of strains isolated from the nares and the peritoneum were found to be of identical plasmid pattern." In a study carried out by Luzar et uZ.,~ the relationship between the nasal carriage of S. aUYeUS and subsequent catheter exit-site infection or peritonitis was assessed in 140 consecutive patients who were new to CAPD. Of these patients 63 were nasal carriers at the initiation of treatment. Luzar et aZ.l found a fourfold higher incidence of exit-site infections in nasal carriers in comparison with non-carriers.
The probability of remaining free of an exitsite infection after 18 months on CAPD was 92% among non-carriers and 54% in carriers (P=O.O12).
Furthermore, among nasal carriers, 11 of 31 episodes of peritonitis were caused by S. auyeus, compared with none of 36 episodes in the non-carriers. In a recent study, patients who were MRSA carriers were found to have an increased rate of exit-site infections and peritonitis.
The risk of being free from MRSA peritonitis after one year on CAPD in the carrier group was 65 vs. 96% in the non-carrier group (PcO.01). Similarly, the risk of being free from an exit-site infection after one year on CAPD was 67% in the carrier group in comparison with 96% in the non-carrier group (P<O*01).'6 The number of patients who had a combination of CAPD-related infections or multiple episodes of peritonitis was also significantly higher in the carrier group than in the non-carrier group (P<O*OOl Subsequent studies have shown the incidence of surgical wound sepsis in nasal carriers of S. aUreUS ranges from 5-19% (Table I) . Moreover, 30-100% of wounds were infected with phage-types that were indistinguishable from those in the patient's nose. In comparison, the postoperative infection rate in non-carriers was between 2-10% ( Table I) . at completion of therapy, all remained free from S. aureus infections at three months followup. In contrast, two out of five patients (40%) who remained nasal culturepositive following mupirocin treatment suffered a S. azweus infection. Ten out of 46 patients (22'Y) o not enrolled in the study but followed concurrently had a significantly higher incidence of S. aweus infection (P=O.O3). In a recent study, the efficacy of mupirocin in the eradication of nasal S. aweus in CAPD patients and the reduction in the incidence of CAPDrelated infections was evaluated.' Ninety-four CAPD patients were enrolled in the study and of these 47.5% were S. aureus nasal carriers. A retrospective assessment of 74 CAPD patients served as historical controls. Two percent mupirocin ointment, applied three times a day for seven days to the patients' nares, eradicated nasal S. UUY~US carriage in 100% of patients. The incidence of S. aureus-related peritonitis and exit-site infections was also significantly reduced following mupirocin treatment.
Only two episodes of peritonitis occurred in CAPD patients, in contrast to 18 episodes in historical controls. Exit-site infections accounted for eight and 19 episodes in CAPD patients and historical controls, respectively.
Surgical patients
The efficacy of mupirocin in the reduction of both S. aweus nasal carriage and subsequent infection in patients undergoing haemodialysis and CAPD has prompted Wenzel' to suggest that sufficient evidence now exists to test the hypothesis that eradication of the carrier state would reduce the incidence of postoperative wound infections with S. QUY~US. Indeed, this has been reported recently in a historically controlled study conducted by Kluytmans et aZ.9 In this study, mupirocin nasal ointment was applied to the nose twice daily for five days, commencing one day prior to the operation, in 629 patients undergoing cardiothoracic surgery during a 12 month period. The overall postoperative rate of infection assessed from 983 historical controls was 8.9%, and of these 3.5% were caused by S. aureus. In comparison, the incidence of all postoperative wound infections, and in particular those caused by S. aweus were significantly reduced during the period of mupirocin treatment, with figures of 1.8% (P<O.OOOl) and 0.6% (P<O.O005), respectively.
S. aweus was isolated from four patients with postoperative wound infections following mupirocin treatment. However, the preoperative nasal cultures from these four patients did not grow S. aweus. Phage-typing showed that two of the isolates were identical to the type isolated previously from the nose of one of the nurses on the ward. Possibly, the infection was acquired postoperatively in the ward. Results, therefore, suggest that preoperative application of mupirocin reduces nasal carriage and reduces the incidence of postoperative wound infections by S. Lzure!us. However, it must be remembered that this conclusion is based on only one historically controlled study. Large randomized, placebocontrolled clinical trials are required to assess more fully the efficacy of applying mupirocin preoperatively to reduce the incidence of postoperative wound infections.
One resistance. Low-and high-level resistance by S. aweus to mupirocin has, however, been reported in the UK and is well documented in several letters to journals42-45 and in the general literature.46'47 Despite this, resistance among S. aUYeUS to mupirocin remains uncommon. A multi-centre UK survey found only 0.3% of 7137 S. aweus isolates to be resistant to mupirocin (MIC >4 mg/L) and only four of these 23 isolates (17%) were highly resistant (MIC >512 mg/L).44 In a separate study, during a MRSA outbreak in a Spanish hospital, an extensive screening programme combined with the use of intranasal mupirocin brought a two-year MRSA outbreak under control, 53 of 530 patients (10%) carried MRSA with low-level resistance to mupirocin (MICs 8-32 mg/L), of which 38 (72%) had previously had mupirocin-sensitive strains.48 The overall incidence of S. aureus strains showing high-level resistance to mupirocin (MICs >512 mg/L) remains extremely low, despite increasing worldwide usage of mupirocin.
Where high level resistance to mupirocin has been encountered, such strains have generally been associated with patients on dermatology wards42,43,45 or others receiving long-term mupirocin therapy of several weeks in duration.44 In this setting, it has been suggested that there may be an environmental reservoir contributing to the spread of mupirocin-resistant isolates.49 Since the development of resistance to mupirocin is a cause for concern and the use of mupirocin preoperatively may encourage the emergence of mupirocin-resistant MRSA, alternative topical and systemic agents are available which can be used to eradicate the nasal carriage of S. azweus with varying degrees of success. Since it is not the intention of this paper to review alternative agents, readers are referred to a review of the subject by Hudson." 
